Royalty Pharma strives to identify creative solutions for the continually evolving challenges faced by our partners in the healthcare industry, and this win-win-win transaction with Eisai and Epizyme is an excellent illustration of the strength and flexibility of Royalty Pharma's business model and our long-term partnership mentality," added Mr. Legorreta. 50 + ROYALTY ACQUISITIONS. (Nasdaq: EPZM), a late-stage biopharmaceutical company developing novel epigenetic therapies, today announced that it exercised its option to sell $50 million of its common stock to Royalty Pharma… Furthermore, Epizyme also gets an 18-month option to divest an additional $50m of its common stock to Royalty Pharma, which holds a three-year option to buy another 2.5 million shares of Epizyme stock at $20 per share.
For more information, please see our Cookie Policy. In addition, investment funds managed by … IR Hero Stats. The transaction contemplates an additional "This transaction allows Eisai to transform its passive financial interest in sales of tazemetostat outside of "The transactions with Royalty Pharma and Pharmakon support our multi-year vision to rewrite therapy for cancer and other serious diseases and to become a fully integrated commercial-stage biopharmaceutical company," commented Goodwin Procter LLP, Dechert LLP, and Maiwald Patentanwalts- und Rechtsanwalts GmbH acted as legal advisors to Royalty Pharma and Akin Gump Strauss Hauer & Feld LLP acted as legal advisor to Pharmakon. Prior to founding Royalty Pharma in 1996, Mr. Legorreta was an investment banker at Lazard Frères in Paris and New York. Royalty Pharma announced today that it has agreed to pay $330 million to purchase Eisai Co., Ltd.’s royalties on future worldwide sales of tazemetostat, Epizyme Inc.’s (Nasdaq: EPZM) lead investigational agent, outside of Japan, and made an equity investment in Epizyme of $100 million, with options to invest up to an additional $100 million in Epizyme common stock.
Any statements in this press release about future expectations, plans and prospects for The sale of Eisai's tazemetostat royalty, a non-strategic passive financial asset, for up to "This investment, Pharmakon's first loan pre-approval, demonstrates our strong support of tazemetostat and Epizyme's management team. Epizyme also has an 18-month option to sell an additional $50 million of its common stock to Royalty Pharma. Under the terms of its agreement with Eisai, Royalty Pharma has acquired Eisai's future worldwide royalties on net sales by Epizyme of tazemetostat outside of … We aspire to change the standard of care for patients and physicians by developing medicines with fundamentally new mechanisms of action. The sale of Eisai's tazemetostat royalty, a non-strategic passive financial asset, for up to "This investment, Pharmakon's first loan pre-approval, demonstrates our strong support of tazemetostat and Epizyme's management team.
The transaction contemplates an additional "This transaction allows Eisai to transform its passive financial interest in sales of tazemetostat outside of "The transactions with Royalty Pharma and Pharmakon support our multi-year vision to rewrite therapy for cancer and other serious diseases and to become a fully integrated commercial-stage biopharmaceutical company," commented Goodwin Procter LLP, Dechert LLP, and Maiwald Patentanwalts- und Rechtsanwalts GmbH acted as legal advisors to Royalty Pharma and Akin Gump Strauss Hauer & Feld LLP acted as legal advisor to Pharmakon.Copyright © 2020 PR Newswire Association LLC. Epizyme also has an 18-month option to sell an additional $50 million of its common stock to Royalty Pharma at then prevailing prices, not to exceed $20 per share, and Royalty Pharma has a three-year option to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share.
Royalty Pharma will pay Eisai up to $330 million to purchase this royalty stream, depending upon FDA approval for certain indications. We use cookies on our website.
In connection with this arrangement, Epizyme has the option to sell an additional $50 million of common stock to Royalty Pharma over the next 18 months at then-prevailing prices, and Royalty Pharma has a three-year warrant to purchase an additional 2,500,000 shares of common stock from Epizyme at $20.00 per share.
Royalty Pharma will make a $100m upfront payment for shares of Epizyme common stock for $15 per share. We work directly with innovators across the life sciences, including research institutions, inventors, and biopharma … CAMBRIDGE, Mass. Tazemetostat is a first-in-class, oral EZH2 inhibitor in clinical development for certain oncology indications, including epithelioid sarcoma and follicular lymphoma. Additionally, in connection with the transaction, Epizyme granted Royalty Pharma a three-year option to purchase an additional 2.5 million shares of Epizyme common stock at $20 per share, and assigned to Royalty Pharma the future royalty streams on tazemetostat sales in Japan … Life Sciences Asia At Epizyme, we are focused on creating medicines that are targeted at specific causes of diseases, that are orally administered, tolerable, easy to take, and that are based on a deep understanding of the patients that will benefit from them. “2020 is set to be a transformational year as we complete our evolution to a commercial enterprise,” said Esperion Announces $510 Million Agreement with Otsuka Pharmaceutical Co., Ltd. in Largest Japan Territory Pharmaceutical Licensing Deal in Last 10 Years Under a collaboration agreement between Epizyme and Eisai, Epizyme is responsible for the development and worldwide commercialization of tazemetostat (outside of Under the terms of its agreement with Eisai, Royalty Pharma has acquired Eisai's future worldwide royalties on net sales by Epizyme of tazemetostat outside of Under the terms of its agreement with Epizyme, Royalty Pharma will make an upfront payment of In addition, Royalty Pharma will make additional payments to Epizyme if annual net sales of tazemetostat outside of Under the terms of the loan agreement with Epizyme, investment funds managed by Pharmakon Advisors will fund "We believe tazemetostat will become an important new option for the treatment of several cancers with high unmet need and are honored to partner with Eisai and Epizyme in these important transactions.
150 + YEARS OF EXPERIENCE. Epizyme’s figure for cash, cash equivalents and marketable securities as of